PositiveID (PositiveID) FCF Margin % : -244.29% (As of Mar. 2018)

View and export this data going back to 2007. Start your Free Trial

What is PositiveID FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PositiveID's Free Cash Flow for the three months ended in Mar. 2018 was $-1.03 Mil. PositiveID's Revenue for the three months ended in Mar. 2018 was $0.42 Mil. Therefore, PositiveID's FCF Margin % for the quarter that ended in Mar. 2018 was -244.29%.

As of today, PositiveID's current FCF Yield % is 0.00%.

The historical rank and industry rank for PositiveID's FCF Margin % or its related term are showing as below:

PSID' s FCF Margin % Range Over the Past 10 Years
Min: -82.51 Med: 0 Max: 0
Current: -82.51

PSID's FCF Margin % is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -11.09 vs PSID: -82.51

PositiveID FCF Margin % Historical Data

The historical data trend for PositiveID's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PositiveID FCF Margin % Chart

PositiveID Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

FCF Margin %

Get a 7-Day Free Trial

-272.38

-153.40

-65.91

-57.04

PositiveID Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
FCF Margin %	Get a 7-Day Free Trial															-26.65	-77.96	-74.37	-47.50	-244.29

Competitive Comparison of PositiveID's FCF Margin %

For the Diagnostics & Research subindustry, PositiveID's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PositiveID's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PositiveID's FCF Margin % distribution charts can be found below:

* The bar in red indicates where PositiveID's FCF Margin % falls into.

PositiveID FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

PositiveID's FCF Margin for the fiscal year that ended in Dec. 2017 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2017 )	/	Revenue (A: Dec. 2017 )
	=	-3.057	/	5.359
	=	-57.04 %

PositiveID's FCF Margin for the quarter that ended in Mar. 2018 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2018 )	/	Revenue (Q: Mar. 2018 )
	=	-1.026	/	0.42
	=	-244.29 %

PositiveID FCF Margin % Related Terms

Thank you for viewing the detailed overview of PositiveID's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

PositiveID (PositiveID) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PositiveID Corp (OTCPK:PSID) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1690 South Congress Avenue, Suite 201, Delray Beach, FL, USA, 33445

Website

http://www.psidcorp.com

PositiveID Corp is a life science tools and diagnostics company. It specializes in the biological detection and molecular diagnostic systems for homeland defense and the global healthcare market. The business activity of the firm includes the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need through its subsidiary. Further, it is also involved in the development of FireflyDX family of products, automated pathogen detection system for rapid diagnostics, both for clinical and point-of-need applications. In addition, it also manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications. All the activities are carried out through the US.

Executives

Ned L Siegel	director	600 WILSHIRE BOULEVARD, LOS ANGELES CA 90017
Michael E Krawitz	director	1690 S CONGRESS AVE, STE 201, DELRAY BEACH FL 33445
Barry M Edelstein	director	1100 GREEN VALLEY ROAD, BRYN MAWR PA 19010
Scott R Silverman	other: Former 10% Owner
Marxe Austin W & Greenhouse David M	10 percent owner	C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Weaver Constance K	director	2900 ESPERANZA CROSSING, 2ND FLOOR, AUSTIN TX 78758
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105